From the 2022 Joint Annual
Meeting (recorded 6/29/2022)
Presented by Rashmi
Kanagal-Shamanna, MD
The application of NGS for
molecular profiling for AML and MDS has allowed for improved classification,
prognostication, and targeted therapeutics. We are now witnessing the emergence
of advanced techniques that can complement conventional cytogenetic analysis to
allow for improved precision medicine care. This presentation will highlight
some of these techniques, and their applications in the care of patients with
myeloid malignancies.
LEARNING OBJECTIVES
At the conclusion of this presentation,
participants will be able to:
- Summarize the standard technologies currently used in clinical laboratories for work-up of hematological malignancies
- Identify potential new techniques that can complement conventional cytogenetic studies in clinical laboratories
- Identify the importance of genomic data for diagnosis, prognostication and therapeutics
CE ACCREDITATION
ASCLS is approved as a provider of continuing
education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ®
Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the
area of CMB (Cytogenetics) will be awarded
to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of
Certification and all states, including Florida and California, as an approved
provider of continuing education for recertification and licensure. ASCLS is an
approved provider with CE Broker for Florida licensees.
LEVEL
OF INSTRUCTION
This Advanced-level
program is appropriate for laboratory professionals working in clinical, public
health and academic settings